For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Tafamidis and Attruby represents a true change. These groundbreaking therapies preserve the transthyretin protein, halting its damaging build-up and lessening the severity of the illness. Patients are now seeing positive outcomes in … Read More